

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

- 1-18. (Cancelled).
19. (Previously Presented) A nucleic acid capable of being specifically bound to a target protein of Ras.
20. (Previously Presented) The nucleic acid as claimed in claim 19, which nucleic acid is an RNA.
21. (Previously Presented) The nucleic acid as claimed in claim 19 or 20, which nucleic acid is specifically bound to the Ras binding domain of the target protein of Ras.
22. (Previously Presented) The nucleic acid as claimed in any of claims 19 to 21, wherein the target protein of Ras is Raf-1.
23. (Currently Amended) The nucleic acid as claimed in claim 22, which nucleic acid is an RNA that is specifically bound to a Ras binding domain (~~R&D~~) (RBD) of Raf-1.
24. (Previously Presented) The nucleic acid as claimed in any of claims 20 to 22, wherein the RNA is an RNA containing at least any one of base sequences of sequence Nos. 1 to 28 of Sequence Listing or a base sequence in which at least one base thereof is deleted and substituted with another base and/or at least one base is added.

25. (Previously Presented) The nucleic acid as claimed in claim 24, wherein the RNA is an RNA containing at least any one of base sequences of sequence Nos. 1 to 8 or sequence Nos. 25 to 28 of Sequence Listing or a base sequence in which at least one base thereof is deleted and substituted with another base and/or at least one base is added.

26. (Previously Presented) A nucleic acid having a complementary base sequence to the nucleic acid as claimed in claim 24 or 25.

27. (Previously Presented) An agent for controlling cell signal transduction which agent is made of the nucleic acid as claimed in any of claims 19 to 26.

28. (Previously Presented) The controlling agent as claimed in claim 27, wherein the nucleic acid is an RNA.

29. (Previously Presented) A method of controlling cell signal transduction using the nucleic acid as claimed in any of claims 19 to 26.

30. (Previously Presented) The method as claimed in claim 29, wherein the nucleic acid is an RNA.

31. (Previously Presented) A pharmaceutical composition containing the nucleic acid as claimed in any of claims 19-26.

32. (Previously Presented) The pharmaceutical composition as claimed in claim 31, which composition is used for treating cancers or inflammatory diseases.

33. (Previously Presented) A method of selecting an RNA having an ability of specific binding to a target protein of Ras, which comprises selecting the RNA having the ability of specific binding to the target protein of Ras from an RNA pool having various base sequences.

34. (Previously Presented) The method as claimed in claim 33, wherein the RNA of the RNA pool having various base sequences is an RNA comprising 20 to 300 bases.

35. (Previously Presented) The method as claimed in claim 33 or 34 wherein the target protein of Ras is Raf-1.